Psilocybin Shocks Researchers: The Latest in Science

In April 2025, the University of California San Francisco published an exciting article. Clinical trials studying the effects of psilocybin on human beings are in their infancy, so when a major university publishes findings such as these, it validates our own experiences with shrooms.

UCSF is currently actively recruiting new test patients who have Parkinson’s Disease and are experiencing depression. Very often, patients suffering from these combined (and related) conditions do not respond to antidepressants. Participation in the study takes approximately 60 hours across 14 visits, over the course of 22 weeks, starting with a 10 mg microdose which increases incrementally each visit.

Researchers involved in the initial study for this project suspected that psilocybin would improve the mood of their test participants, but they did not expect the high degree of improvement following psilocybin treatments, and how long these positive effects would last.

According to the UCSF article, participants had significant improvements in their mood, cognition, and motor symptoms at both their one-week and one-month follow-up appointments. The research team evaluated the participants’ mood again three months after their psilocybin sessions and found it was still significantly improved. These findings could be the result of physical changes or emotional changes that lead to physical changes. For example, participants felt well enough to become more social and physically active, which in turn helped improve their mood, and a cycle of positive change was initiated.

“These results raise the exciting possibility that psilocybin may help the brain repair itself,” says lead researcher Joshua Woolley, MD, Phd. This result is especially exciting because this study represents the first time an active psychedelic ingredient has been tested on patients with any neurodegenerative disease.

One day, science will catch up to what we at Canada Shrooms already know. We know that psilocybin in micro doses improves your mood and can stabilize your thinking, cognition, and ability to relate to others in almost any setting. We also know that macro dosing can lead to fascinating introspective discoveries, allowing you to think differently about yourself and others long-term and even, sometimes, for good.

These UCSF studies are funded by an anonymous donor. Of course we can only speculate, but donors with Parkinson’s disease and the means to support research at this level include Michael J. Fox, Neil Diamond, Alan Alda, and George W. Bush. At the very least, we hope this kind of research can set the record straight when it comes to the cognitive benefits of delightful, mysterious, impactful magic mushrooms.

To find out if your brain responds well to psilocybin microdosing, visit our store now!